Teplizumab: a promising intervention for delaying type 1 diabetes progression
Type 1 diabetes (T1D) arises from an autoimmune attack on pancreatic beta cells, leading to a reliance on external insulin to maintain glucose levels. In recent years, research has increasingly focused on preventive strategies for individuals at high risk. A promising new intervention in this field...
Saved in:
| Main Authors: | Muhammad Rizwan Saleem, Muhammad Talha Khan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1533748/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody Engineering Toward Enhancement of Teplizumab Anti-CD3 Binding Affinity in Type 1 Diabetes Prevention and Treatment
by: Fateme Sefid, et al.
Published: (2025-05-01) -
Innovations in Pharmacotherapy of Diabetes: A Review of Latest Reports
by: Katarzyna Czechowska, et al.
Published: (2025-07-01) -
Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
by: Alexander J. O’Donovan, et al.
Published: (2024-11-01) -
Clinical features among adult‐onset type 1 diabetes, distribution of subtypes, and differences in probable and definite slowly progressive insulin‐dependent diabetes mellitus: A single hospital‐based study over a 13‐year period
by: Hiroko Takaike, et al.
Published: (2025-05-01) -
Research progress of nutrition intervention in diabetes mellitus
by: XI Jiecan, et al.
Published: (2024-09-01)